Date:11/15/2009

348,018 Prepaid expenses and deposits 877,260 933,297 Deferred tax assets 678,620 1,189,831 Total current assets 98,594,755 61,338,195 Property, plant and equipment 21,426,879 19,262,099 Long term inventories 3,110,828 942,514 Deferred tax asset 532,854 569,937 Licenses and permits 794,567 1,090,477 Total assets $124,459,883 $83,203,222 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Loans payable $21,937,522 $8,024,277 Accounts payable and accrued liabilities 14,301,303 11,909,037 Income tax payable 2,962,831 - Due to related parties 46,971 46,971 Dividends payable to non-controlling shareholder of Sinovac Beijing 115,957 115,677 Deferred tax liability 768,876 - Deferred research grants 1,051,099 1,182,703 Total current liabilities 41,184,559 21,278,665 Deferred government grants 2,690,382 2,836,994 Loan payable - 2,188,439 Deferred revenue 9,798,760 - Long-term debt 12,489,142 5,025,433 Total liabilities 53,673,701 26,304,098 Commitments and contingencies STOCKHOLDERS' EQUITY Preferred stock - - Authorized 50,000,000 shares at par value of $0.001 each Issued and outs
'/>"/>

SOURCE Sinovac Biotech Co., Ltd. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related biology technology :

1. Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government
2. Sinovac Receives Certificate of Approval to Distribute Panflu (H5N1) Vaccine in Hong Kong
3. Sinovac to Present at 2009 UBS Global Life Sciences Conference
4. Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine
5. Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government
6. Sinovac Obtains Production License for H1N1 Vaccine
7. Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results
8. Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
9. Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
10. Sinovac Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A (H1N1)
11. Sinovac Adjourns 2008 Annual General Meeting